Pay in 4 interest-free payments of $7.37 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Crossing barriers from blood-to-brain and academia-to-industry
Careful consideration of patient selection criteria and possible side effects, such as gastrointestinal discomfort and hypoglycemia, will be important when using GLP-1RAs for the treatment of IIH
The outcome of this meeting often determines the submission timeline
Black cohosh (Cimicifuga spp.) for menopausal symptoms
Vasodilatory actions of glucagon-like peptide 1 are preserved in skeletal and cardiac muscle microvasculature but not in conduit artery in obese humans with vascular insulin resistance
BENEFITS Triple receptor activation studied for simultaneous GLP-1, GIP, and glucagon engagement Metabolic research explored in Phase 2 clinical trials with notable body-composition results Glucagon component linked to thermogenesis and energy-expenditure pathways Next-generation compound investigated as an advancement over dual-agonist approaches Comparative pharmacology assessed alongside mono- and dual-agonists in research settings WHAT RESEARCHERS LOOK AT Triple-agonist binding affinity across GLP-1, GIP, and glucagon receptors Additive effects of glucagon-receptor activation on energy expenditure Dose-response and tolerability profiling from clinical-trial data Comparative outcomes vs tirzepatide and semaglutide Pharmacokinetic profiling and receptor selectivity QUICK SPECS Form: Lyophilized peptide powder Net per vial: 10 mg Purity: 99% (HPLC verified) Identity: MS-verified (per COA) Storage: 28C, protect from light and moisture Reconstitution: Use bacteriostatic water (sold separately) IDENTITY BASICS CAS: 2381089-83-2 Classification: Triple GLP-1/GIP/glucagon receptor agonist WHY CHOOSE DURHAM PEPTIDES FOR RETATRUTIDE
US$ 20.10
US$ 22.38
US$ 21.98
US$ 21.11
US$ 23.78
